Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

What Does the Published Research Say About IGF1-LR3?

This summary draws only from the supplied synthesis packet and keeps human evidence, preclinical results, and mechanistic findings distinct. Claims are limited to what the cited studies support.

Research Context

  • The packet is driven by animal, in vitro, and tissue-engineering studies; it does not include human clinical outcome trials for LR3 IGF-1 or native IGF-1. The packet advises against broad human-efficacy framing.
  • Several findings concern native IGF-1 rather than LR3 IGF-1; results are context-dependent across analogue, species, age, route, and delivery format. Findings for IGF-1 and LR3 should not be treated as interchangeable.

Key Takeaway

Published IGF-1 LR3 evidence is primarily preclinical and model-specific. Some studies report biomarker or tissue changes, but there are no human efficacy or safety outcomes in this packet, and translational relevance remains uncertain.

Direct Answer

  • Direct human efficacy or safety evidence for IGF-1 LR3 is absent in this packet.
  • Preclinical studies report heterogeneous, model-specific effects for LR3 IGF-1 and/or native IGF-1 across growth, metabolism, neuropathology markers, and nerve repair, with outcomes varying by analogue, species, age, route, and delivery construct.
  • Mechanistic and structural work supports biological plausibility but does not establish clinical utility. Dosing or safety conclusions for humans are not supported by the packet.

Evidence by Category

Human evidence

  • No controlled human clinical trials or direct human-outcome studies for LR3 IGF-1 are included in the packet.
  • The packet does not support dosing or generalized safety conclusions for humans.

Animal and tissue-engineering studies (preclinical)

  • Growth and gut proliferation (rats; LR3 IGF-1 and/or native IGF-1): Systemic infusion of IGF-1 or LR3 IGF-1 stimulated visceral organ growth and gut tissue proliferation in suckling rats [pubmed:9124573]. These neonatal rat findings are not generalizable to humans.
  • Fetal growth (sheep; native IGF-1 vs LR3 IGF-1):
  • Native IGF-1 infusion increased organ growth in fetal sheep without evidence of increased placental/fetal nutrient transfer [pubmed:33427051]. This prenatal agricultural model has uncertain relevance to adult human outcomes.
  • LR3 IGF-1 did not promote growth in late-gestation growth-restricted fetal sheep [pubmed:39679943]. Model- and condition-specific context limits extrapolation.
  • Islet function (sheep; native IGF-1): A 1-week native IGF-1 infusion in late-gestation fetal sheep reduced glucose-stimulated insulin secretion due to an intrinsic islet defect in that model [pubmed:33938236]; implications beyond this prenatal context are unknown.
  • Neuropathology marker vs function (mice; LR3 IGF-1, intranasal): Intranasal LR3 IGF-1 promoted amyloid plaque remodeling in male 5XFAD mice but did not preserve cognitive function [pubmed:39610283]. Biomarker changes did not translate to behavioral benefit in this model.
  • Peripheral nerve repair (rats; LR3 IGF-1, localized construct): A decellularized Alstroemeria stem-based conduit with GelMA and controlled LR3 IGF-1 release reported enhanced sciatic nerve regeneration in a rat model; effects pertain to this localized tissue-engineering context [pubmed:41015370] and should not be extrapolated to systemic delivery.
  • Protein metabolism (cattle; LR3 IGF-1): LR3 IGF-1 affected protein metabolism in beef heifers [pubmed:10370861]; this agricultural model has uncertain human relevance.
  • Route- and age-dependent intestinal effects (rats; LR3 IGF-1 and/or native IGF-1):
  • LR3 IGF-1 showed preferential intestinal delivery compared with native IGF-1 in preweaning and adult rats [pubmed:12697696]. This rat finding does not establish human oral bioavailability.
  • Systemic, but not orogastric, delivery of IGF-1 or LR3 IGF-1 increased intestinal disaccharidase activity in suckling rats [pubmed:9803447]. Lack of effect via the orogastric route in this model should not be overinterpreted for humans.
  • Reproductive endpoints (rats; LR3 IGF-1): Older reports describe enhanced superovulatory response with LR3 IGF-1 infusion; methodological detail is limited [crossref:10.1016/S0015-0282(97)84896-0; crossref:10.1016/S0015-0282(97)90811-6]. These findings should be viewed as preliminary.

Applied/analytical and production context

  • Recombinant expression approaches (including Pichia pastoris fusions) and physicochemical characterization of LR3 IGF-1 inclusion bodies are reported [crossref:10.1007/s00253-023-12606-0; crossref:10.1021/bp010058x].
  • Detection of His-tagged LR3 IGF-1 in an unregulated product is described in an analytical report; this is descriptive and nonclinical [crossref:10.1016/j.ghir.2010.07.001].

Mechanistic and in vitro evidence

  • Structure: Solution NMR characterized the structure and backbone dynamics of LR3 IGF-1 [pubmed:10744677].
  • Signaling modulation (cell system–specific): N-linked glycosylation in Chinese hamster ovary cells was critical for IGF-1 signaling in that system; this study does not distinguish LR3-specific effects [pubmed:36499281].
  • Hematopoietic cell biology: IGF-1 and IGF-binding proteins were involved in proliferation and differentiation of murine bone marrow–derived macrophage precursors in vitro/ex vivo [pubmed:9867252].

Gaps and limits

  • No direct human efficacy, safety, dose–response, or durability data for LR3 IGF-1 are included in the packet.
  • Findings differ by analogue (native IGF-1 vs LR3 IGF-1), species, age, route, and delivery construct; results from one context do not generalize across models.
  • Rat intestinal-delivery findings should not be taken as evidence of human oral bioavailability [pubmed:12697696; pubmed:9803447].
  • Changes in disease biomarkers without corresponding functional benefit (e.g., amyloid plaque remodeling without cognitive preservation) leave clinical relevance uncertain [pubmed:39610283].
  • Localized tissue-engineering results (e.g., nerve conduit delivery) should not be extrapolated to systemic administration or different indications [pubmed:41015370].
  • The product-detection report is descriptive and does not evaluate safety, efficacy, or manufacturing quality [crossref:10.1016/j.ghir.2010.07.001].

FAQ

  • Is there human clinical evidence for IGF-1 LR3 in this packet?
  • No. The packet includes no controlled human clinical trials or direct human-outcome studies for LR3 IGF-1.
  • Does IGF-1 LR3 improve cognition in Alzheimer’s-model mice?
  • In male 5XFAD mice, intranasal LR3 IGF-1 remodeled amyloid plaques but did not preserve cognitive function [pubmed:39610283].
  • Do rat intestinal-delivery studies imply oral bioavailability in humans?
  • No. Preferential intestinal delivery and disaccharidase findings are in rats and do not establish human oral bioavailability [pubmed:12697696; pubmed:9803447].
  • Are IGF-1 and LR3 IGF-1 findings interchangeable?
  • No. Effects vary by analogue, species, age, route, and delivery construct; results should not be conflated.
  • What do prenatal or agricultural models (fetal sheep, heifers) tell us about humans?
  • They inform biology in those contexts but have uncertain relevance to adult human outcomes [pubmed:33427051; pubmed:33938236; pubmed:10370861].

References

  • IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. https://pubmed.ncbi.nlm.nih.gov/39679943/
  • Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. https://pubmed.ncbi.nlm.nih.gov/39610283/
  • Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. https://pubmed.ncbi.nlm.nih.gov/41015370/
  • Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. https://pubmed.ncbi.nlm.nih.gov/10370861/
  • IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus. https://pubmed.ncbi.nlm.nih.gov/33427051/
  • Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. https://pubmed.ncbi.nlm.nih.gov/33938236/
  • Preferential intestinal delivery of long[Arg3] insulin-like growth factor (LR3IGF-I) over IGF-I in preweaning and adult rats. https://pubmed.ncbi.nlm.nih.gov/12697696/
  • Systemically but not orogastrically delivered insulin-like growth factor (IGF)-I and long [Arg3]IGF-I stimulates intestinal disaccharidase activity in two age groups of suckling rats. https://pubmed.ncbi.nlm.nih.gov/9803447/
  • N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling. https://pubmed.ncbi.nlm.nih.gov/36499281/
  • Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors. https://pubmed.ncbi.nlm.nih.gov/9867252/
  • Systemic infusion of IGF-I or LR(3)IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. https://pubmed.ncbi.nlm.nih.gov/9124573/
  • Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I. https://pubmed.ncbi.nlm.nih.gov/10744677/
  • In Vivo Infusion With IGF-I Analogue, Long Arg3-Insulin-Like Growth Factor-I (LR3-IGF-I) Enhances Superovulatory Response in Rats. https://doi.org/10.1016/s0015-0282(97)84896-0
  • O-179 In vivo infusion with IGF-I analogue, long Arg3-insulin-like growth factor-I (LR3-IGF-I) enhances superovulatory response in rats. https://doi.org/10.1016/S0015-0282(97)90811-6
  • Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. https://doi.org/10.1007/s00253-023-12606-0
  • Physicochemical Characteristics of LR3-IGF1 Protein Inclusion Bodies: Electrophoretic Mobility Studies. https://doi.org/10.1021/bp010058x
  • Detection of His-tagged Long-R3-IGF-I in a black market product. https://doi.org/10.1016/j.ghir.2010.07.001